Evidence map›Paper›PMID 39803448›Full record

ArticlebioRxiv : the preprint server for biology2025

Flexibility in PAM Recognition Expands DNA Targeting in xCas9.

Kazi A Hossain, Lukasz Nierzwicki, Modesto Orozco, Jacek Czub, Giulia Palermo

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Kazi A HossainDepartment of Bioengineering, University of California Riverside, 900 University Avenue, Riverside, CA 52512, United States.ORCID 0000-0002-1149-964X
Lukasz NierzwickiDepartment of Bioengineering, University of California Riverside, 900 University Avenue, Riverside, CA 52512, United States.
Modesto OrozcoInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain.ORCID 0000-0002-8608-3278
Jacek CzubDepartment of Physical Chemistry, Gdańsk University of Technology, Gdańsk 80-233, Poland.
Giulia PalermoDepartment of Bioengineering, University of California Riverside, 900 University Avenue, Riverside, CA 52512, United States.ORCID 0000-0003-1404-8737

Funding

Investigating the metal-dependent function, allostery and inhibition of CRISPR-Cas9R01GM141329 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI PALERMO, GIULIA · 2021 to 2025
$1.7M
NIGMS NIH HHS R01 GM141329
6 · The paper itself

Abstract

xCas9 is an evolved variant of the CRISPR-Cas9 genome editing system, engineered to improve specificity and reduce undesired off-target effects. How xCas9 expands the DNA targeting capability of Cas9 by recognizing a series of alternative Protospacer Adjacent Motif (PAM) sequences while ignoring others is unknown. Here, we elucidate the molecular mechanism underlying xCas9's expanded PAM recognition and provide critical insights for expanding DNA targeting. We demonstrate that while wild-type Cas9 enforces stringent guanine selection through the rigidity of its interacting arginine dyad, xCas9 introduces flexibility in R1335, enabling selective recognition of specific PAM sequences. This increased flexibility confers a pronounced entropic preference, which also improves recognition of the canonical TGG PAM. Furthermore, xCas9 enhances DNA binding to alternative PAM sequences during the early evolution cycles, while favouring binding to the canonical PAM in the final evolution cycle. This dual functionality highlights how xCas9 broadens PAM recognition and underscores the importance of fine-tuning the flexibility of the PAM-interacting cleft as a key strategy for expanding the DNA targeting potential of CRISPR-Cas systems. These findings deepen our understanding of DNA recognition in xCas9 and may apply to other CRISPR-Cas systems with similar PAM recognition requirements.

Indexed as

CRISPR-Cas9entropygenome editingprotein-DNAprotein dynamicsRNA

Identifiers

PMID39803448
PMCPMC11722361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.